Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer.
Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overall survival, time to skeletal-related events, and health-related quality of life. Apart from radium-223, the cytotoxic chemotherapy agents docetaxel and cabazitaxel, androgen biosynthesis inhibitor abiraterone acetate, novel anti-androgen enzalutamide, and immunotherapy sipuleucel-T have also been shown to improve survival of men with advanced prostate cancer in Phase III trials. This review will outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 in changing treatment paradigms.
Written by:
Mukherji D, El Dika I, Temraz S, Haidar M, Shamseddine A. Are you the author?
Department of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon; Department of Nuclear Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Reference: Ther Clin Risk Manag. 2014 May 23;10:373-380.
doi: 10.2147/TCRM.S45667
PubMed Abstract
PMID: 24920911
